Skip to main content
Equibles
MNPR logo

MNPR · Monopar Therapeutics · Debt

Track MNPR — free

Use MNPR with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research MNPR.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$71.42 +4.20 (+6.25%) At close · Nov 6
Russell 2000 member Rebalance outlook locked
Market Cap
$479.38M
Shares
6.71M
Volume · Nov 6 94.21K Avg daily vol (3M) 164.19K

Debt Profile

Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.

Read debt and covenant terms in your AI or your code through MCP and the API →

Reported debt balances

Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.

Reported balanceAs ofAmountSource
Operating lease liabilities 2026-06-30 USD 205,663 10-Q filed 2026-08-12
Related accounting measures — not additional borrowing

Carrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year.

Current operating lease liabilities
USD 97,834
Noncurrent operating lease liabilities
USD 107,829
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.

Covenants

Covenant terms have not yet been verified for this profile.

The balance figures do not establish whether covenants apply or whether the company complies with them.

Loans, facilities and notes

The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.

Key facts CIK 1645469 CUSIP 61023L207 13F (30d) 28 filings 24 filers Visit website Investor relations